» Articles » PMID: 21305657

Pure Intronic Rearrangements Leading to Aberrant Pseudoexon Inclusion in Dystrophinopathy: a New Class of Mutations?

Overview
Journal Hum Mutat
Specialty Genetics
Date 2011 Feb 10
PMID 21305657
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

We report on two unprecedented cases of pseudoexon (PE) activation in the DMD gene resulting from pure intronic double-deletion events that possibly involve microhomology-mediated mechanisms. Array comparative genomic hybridization analysis and direct genomic sequencing allowed us to elucidate the causes of the pathological PE inclusion detected in the RNA of the patients. In the first case (Duchenne phenotype), we showed that the inserted 387-bp PE was originated from an inverted ∼57 kb genomic region of intron 44 flanked by two deleted ∼52 kb and ∼1 kb segments. In the second case (Becker phenotype), we identified in intron 56 two small deletions of 592 bp (del 1) and 29 bp (del 2) directly flanking a 166-bp PE located in very close proximity (134 bp) to exon 57. The key role of del 1 in PE activation was established by using splicing reporter minigenes. However, the analysis of mutant constructs failed to identify cis elements that regulate the inclusion of the PE and suggested that other splicing regulatory factors may be involved such as RNA structure. Our study introduces a new class of mutations in the DMD gene and emphasizes the potential role of underdetected intronic rearrangements in human diseases.

Citing Articles

DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy.

Ge L, Yang Y, Yang Y, Chen Y, Tao N, Zhang L Open Med (Wars). 2024; 19(1):20240916.

PMID: 39588385 PMC: 11587917. DOI: 10.1515/med-2024-0916.


Analysis of 200 unrelated individuals with a constitutional NF1 deep intronic pathogenic variant reveals that variants flanking the alternatively spliced NF1 exon 31 [23a] cause a classical neurofibromatosis type 1 phenotype while altering....

Koczkowska M, Chen Y, Xie J, Callens T, Gomes A, Wimmer K Hum Genet. 2023; 142(7):849-861.

PMID: 37186028 PMC: 10329576. DOI: 10.1007/s00439-023-02555-z.


A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review.

Chung Liang L, Sulaiman N, Yazid M Front Bioeng Biotechnol. 2022; 10:833833.

PMID: 35402409 PMC: 8984139. DOI: 10.3389/fbioe.2022.833833.


Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy.

Waldrop M, Moore S, Mathews K, Darbro B, Medne L, Finkel R Hum Mutat. 2022; 43(4):511-528.

PMID: 35165973 PMC: 9901284. DOI: 10.1002/humu.24343.


Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.

Keegan N, Wilton S, Fletcher S Front Genet. 2022; 12:806946.

PMID: 35140743 PMC: 8819188. DOI: 10.3389/fgene.2021.806946.